株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界のタンパク質医薬品市場

Protein Drugs

発行 Global Industry Analysts, Inc. 商品コード 134322
出版日 ページ情報 英文 524 Pages
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
世界のタンパク質医薬品市場 Protein Drugs
出版日: 2010年08月01日 ページ情報: 英文 524 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

当レポートでは、世界のタンパク質医薬品市場について調査し、市場の概要と動向、新製品開発、製品認可、業界活動、参入する企業のプロファイルと競合状況などをまとめ、概略下記の構成でお届けいたします。

第1章 イントロダクション、方法論、製品定義

第2章 エグゼクティブサマリ

  • 業界概要
    • 概要
    • タンパク質医薬品はベストセラー
    • 主な統計
    • 競合シナリオ
    • 不況の影響
    • 不況ではなくジェネリック医薬品との競合が売上減少の原因
    • 新興市場におけるアンメットニーズが肥沃な環境を提供
    • 主な市場動向と課題
    • 地域別市場
  • 製品概要
    • イントロダクション
    • 構造的情報
    • タンパク質医薬品源
    • 様々な種類
    • 応用
    • バイオテクノロジーにおける重要性
    • 弱点
  • 製品導入・上市
  • 近年の業界活動
  • 主要企業
  • 世界市場見通し

第3章 競合状況

  • 企業プロファイル:56社(事業部・子会社含め58社)
    • 米国
    • カナダ
    • 日本
    • 欧州
    • アジア太平洋地域(日本を除く)
目次
Product Code: MCP-6377

Abstract

This report analyzes the Global market for Protein Drugs in US$ Million by the following Drug Classes - Antibodies, Blood Products, Cytokines, Peptide Hormones, Vaccines, and Others (Including Peptide Antibiotics and Enzymes). Annual estimates and forecasts are provided for the period 2006 through 2015. The report profiles 56 companies including many key and niche players such as Abbott Laboratories, Inc., Alexion Pharmaceuticals, Inc., Amgen, Inc., Biogen Idec, Bristol-Myers Squibb Company, Medarex, Inc., Crucell N.V., Dendreon Corporation, Eli Lilly and Company, Emergent BioSolutions, Inc., Genentech, Inc., Johnson & Johnson, Centocor Ortho Biotech, Inc., MedImmune, Inc., Merck Serono S.A., Schering-Plough Corporation, UCB Group, Unigene Laboratories, Inc., and Vaccinogen, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
  • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • A Prelude
  • Protein Drugs Are the Best Sellers
  • Key Statistics:
  • Table 1: World Market for Biopharmaceuticals (2009): Top 10 Brands Ranked by Dollar Sales (In US$ Billion) (includes corresponding Graph/Chart)
  • Table 2: World Market for Biopharmaceuticals (2007 & 2008): Top 15 Brands Ranked by Dollar Sales (In US$ Billion)
  • Competitive Scenario
  • Intensifying Consolidation Activity
  • Impact of Recession: A Review
  • Impact of Recession on Drug Sales
  • Impact of Recession on R&D Activities
  • Not Recession, But Generic Competition Will Cause Sales Erosion
  • Patent Expiration
  • Impending Patent Expiry For Key Protein Drugs
  • Patent Expirations For Key Protein and Peptide Drugs in the Recent Past
  • Follow-on Biologics: An Opportunity in Adverse Conditions
  • Legal and Scientific Viability of Follow-on Protein Drugs
  • MAb: A Market Better Protected from Generic Competition
  • Approved Monoclonal Antibodies in the Market
  • Unmet Medical Needs in Emerging Markets Provides Fertile Environment
  • Key Market Trends & Issues: A Review
  • Continuous Fight Against Diseases: A Key Propeller for Growth
  • Population Aging Makes Rise Of Protein Drugs Inevitable
  • Ability to Address Wide Gamut of Diseases is Key to Success
  • Combination Biologics Can Offer New Treatment Possibilities
  • Shift Towards Humanized and Fully Human Antibodies
  • Biotechnology Gives a New Direction
  • Innovative Drug Delivery Methods: The Need of the Hour
  • Companies Seek Partnerships and Collaborations to Sustain Profit Margins
  • Increasing Demand for Protein A in Mab Manufacturing
  • Rising Number of MAbs Under Clinical Trials
  • Major Protein Drugs in Pipeline As of 2009
  • Untapped Pharmacological Potential of GPCRs Ignites Interest
  • Increased Reliance On Contract Manufacturing
  • Reimbursement & Price Sensitivity Are Key Challenges
  • Manufacturing Bottleneck
  • High Costs Impede Penetration
  • A Special Focus On Key Regional Markets
  • United States
  • Market Overview
  • Biologicals: A Review
  • Biologicals: A Costly Preposition
  • Recombinant Proteins To Continue Their Significance as Key Biologic Products
  • Recombinant Blood-Related Agents to Continue Their Market Growth
  • Early Generic Competition Will Unsettle Revenues for Key Protein Drugs
  • Key Statistics:
  • Table 3: US Market for Protein Therapeutics (2010): Percentage Share Breakdown of Dollar Sales for Key Therapy Area (includes corresponding Graph/Chart)
  • China
  • Market Overview
  • China to Emerge As Biosimilar Major
  • Lack of Regulatory Framework
  • India
  • Market Overview
  • Indian Pharma Companies Gear Up to Grab a Big Slice of Global Follow-On Biologics Market
  • Openness in US Market Will Provide Opportunities

2. PRODUCT OVERVIEW

  • An Introduction
  • Structural Information
  • Classification of Proteins
  • Sources of Protein Drugs
  • Types of Protein-Based Drugs
  • Cytokines
  • Clotting factors
  • Hormones
  • Monoclonal Antibodies (Mabs)
  • Vaccines
  • Different Types of Protein Drugs
  • Applications
  • Significance of Biotechnology in Protein-Based Drugs
  • Hybridoma Cell Technology
  • Recombinant DNA Technology
  • Production of Protein Drugs through Transgenic Animals
  • Disadvantages of Protein-based Drugs
  • Immunogenicity of Protein-Based Drugs

3. PRODUCT INTRODUCTIONS/LAUNCHES

  • Millipore Launches Magna RIPTM RNA-binding ProteinImmunoprecipitation Kit
  • Millipore Unveils AllostericProfilerTM Service
  • Caliper Life Sciences Introduces Two Products to Expand LabChip GX Product Range
  • BioDtech Introduces EndoPrep
  • Amgen Introduces Vectibix
  • Trevigen Introduces Mouse Monoclonal Antibody
  • UCB Receives FDA Approval for Cimzia®
  • MD Biosciences Launches Keratocan and Lumican Monoclonal Antibodies
  • PhyNexus Introduces PhyTip® ProPlus™ Columns

4. RECENT INDUSTRY ACTIVITY

  • Novartis Vaccines Receives EC Approval for Menveo®
  • Lonza Takes Over Algonomics
  • Daicel Chemical Takes Over ChromTech
  • Roche Licenses ProTek Stabilisation Technology of Aegis Therapeutics
  • Lonza to Manufacture Arzerra
  • Sanofi Pasteur Receives FDA Approval for Fluzone® High-Dose Vaccine
  • Maxygen and Astellas Complete Joint Venture Transaction
  • Sanofi Pasteur' s Panenza® and Humenza® Vaccines Elicit Strong Immune Response
  • Amgen Collaborates with GSK
  • Nabi Biopharmaceuticals Inks Licensing Agreement with GSK
  • Wyeth Pharmaceuticals and Ambrx Enter into Strategic Alliance
  • OPKO Health and Academia Sinica Ink Exclusive License Agreement
  • Seattle Life Sciences and ZymoGenetics Enter into Licensing Pact
  • Roche and Covagen Enter into Collaboration
  • Lonza to Manufacture Biologics for LFB and Medarex
  • Protgen Establishes Protein Drug Innovation Center in Beijing
  • National Cheng Kung University Inks MoU with ScinoPharm Taiwan
  • Novo Nordisk and ZymoGenetics Signs Licensing Agreement
  • Lipoxen Signs Collaboration Agreement with Pharmasynthez
  • Debiopharm Group Inks License Agreement with Curis
  • Bristol-Myers Squibb Acquires Medarex
  • Sanofi Pasteur Signs Licensing Agreement with Syntiron
  • Sanofi Pasteur Inks Strategic Agreement with ShanH
  • Access Pharmaceuticals Acquires Somanta Pharmaceuticals
  • IMUC Completes Molecular Antibody Technology Acquisition
  • Callisto Merger Corporation Merges with Celldex Therapeutics
  • Arana and Kyowa Hakko Sign Agreement to Jointly Develop ART 104
  • Eusa Sells Antibody Research Business
  • Dyax and Sanofi-Aventis Sign Agreements
  • HGS Enters into Antibody Collaboration Agreement with Xencor
  • Wyeth Pharmaceuticals and Biovitrum Extend ReFacto Supply Agreement
  • Caprotec Bioanalytics and Merck Ink Collaboration Agreement
  • Biomonitor Snaps Up Neutekbio
  • GE Healthcare Takes Over MicroCal
  • Arana Therapeutics Enters into Collaboration with Greenovation Biotech
  • Bayer Healthcare Acquires Hemophilia Program Assets of Maxygen
  • Sanofi Pasteur Holding Purchases Acambis
  • GlaxoSmithKline Enters into Strategic Alliance with Archemix
  • Talecris Biotherapeutics Inks License Agreement with Crucell
  • Polyphor Signs Exclusive Licensing Agreement with Allergan
  • Morphotek® Enters into Partnership with Pivotal BioSciences
  • PharmAthene Snaps Up Biodefence Vaccines Business of Avercia Biologics
  • Raven Biotechnologies and CMC ICOS Biologics Ink an Agreement
  • MacroGenics Purchases Raven Biotechnologies

5. FOCUS ON SELECT PLAYERS

  • Abbott Laboratories, Inc. (US)
  • Alexion Pharmaceuticals, Inc. (US)
  • Amgen, Inc. (US)
  • Biogen Idec (US)
  • Bristol-Myers Squibb Company (US)
  • Medarex, Inc. (US)
  • Crucell N.V. (The Netherlands)
  • Dendreon Corporation (US)
  • Eli Lilly and Company (US)
  • Emergent BioSolutions, Inc. (US)
  • Genentech, Inc. (US)
  • Johnson & Johnson (US)
  • Centocor Ortho Biotech, Inc. (US)
  • MedImmune, Inc. (US)
  • Merck Serono S.A. (Switzerland)
  • Schering-Plough Corporation (US)
  • UCB Group (Belgium)
  • Unigene Laboratories, Inc. (US)
  • Vaccinogen, Inc. (US)

6. GLOBAL MARKET PERSPECTIVE

  • Table 4: World Recent Past, Current & Future Analysis for Protein Drugs by Geographic Region - US and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 5: World 10-Year Perspective for Protein Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US and Rest of World Markets for Years 2006, 2009, and 2015
  • Table 6: World Recent Past, Current and Future Analysis for Protein Drugs by Drug Type - Antibodies, Blood Products, Cytokines, Peptide Hormones, Vaccines, and Other Drugs Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 7: World 10-Year Perspective for Protein Drugs by Drug Type - Percentage Breakdown of Dollar Sales for Antibodies, Blood Products, Cytokines, Peptide Hormones, Vaccines, and Other Drugs for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)

III. COMPETITIVE LANDSCAPE

Back to Top